HealthCapital Newsletter September 2018
HealthCapital Newsletter September 2018 If this newsletter is not displayed properly, please click here. Land Brandenburg und be Berlin
load images
HealthCapital Newsletter September 2018

Dear Sir or Madam,

Healthcare is more than medicine. With this in mind, one of the most important forums for global health issues, the World Health Summit, was established in Berlin ten years ago. Heads of state, leading scientists, board members of industrial companies, international NGOs, and startups from all over the world will once again meet in Berlin to discuss global health issues from October 14-16 . In this issue of our newsletter, find out who else besides Angela Merkel and Bill Gates is expected at this year's World Health Summit in Berlin.

In autumn, the capital region offers further opportunities to exchange ideas on important topics of the future: in addition to the RegMed Forum on Smart Medical Devices on October 18, which will address the latest technologies in the field of regenerative medicine, HIMMS Impact18 is hosting a forum on the digital transformation and "Big Data" and their effects on medicine from October 17-18.
Be there and get involved in the discussion at one or more of the many events taking place this autumn and get to know the innovation drivers in Berlin-Brandenburg!

 
 

Portrait

 
load images

10 Years of The World Health Summit in Berlin

Without politics, medicine quickly reaches its limits. This realization led Professor Detlev Ganten to launch the World Health Summit in 2009 – just in time for the 300th anniversary of the Charité – Universitätsmedizin Berlin. Since then, the goal of the annual meeting has been to strengthen the voice of science, ultimately contributing to better policy decisions. This year, the international players from all areas of the health care sector will be meeting in the Kosmos Berlin from October 14-16 for the tenth time – time to look back and forward.

Read more...

 


Business News


Berlin Health Innovations invests in 18 pioneering innovations

The validation fund of Berlin Health Innovations in cooperation with SPARK Berlin is entering its first round. 18 selected teams from the Charité – Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) will receive intensive mentoring and coaching as well as 3.4 million euros in funding for their innovative translational projects in the fields of pharma/drug development, medical technology, diagnostics and digital health.

Read more...

 

MOLOGEN and ONCOLOGIE: Global assignment and codevelopment agreement relating to MOLOGEN’s lead compound lefitolimod

The biopharmaceutical company MOLOGEN AG signed, with the consent of the Supervisory Board, a term sheet outlining the framework for a global assignment of all intellectual property and other rights in MOLOGEN’s lead compound lefitolimod to ONCOLOGIE and an expansion of the existing global codevelopment agreement between MOLOGEN and ONCOLOGIE. The potential total deal value would be over €1 billion plus low double digit royalties on net sales, representing an attractive upside for MOLOGEN. MOLOGEN would receive a near-term consideration of €23 million. This transaction would secure the major part of the funding for the pivotal IMPALA study until read-out, projected for 2020.

Read more...

 

Citoxlab signs investment and partnership deal with Experimental Pharmacology and Oncology Berlin-Buch GmbH (EPO)

Investment in the German CRO, specialized in the preclinical assessment of new anticancer drugs, strengthens Citoxlab’s pharmacology portfolio, which will benefit from many synergies with preclinical safety and biomarkers services already provided by Citoxlab

Read more...

 

Discovering the Berlin Digital Health ecosystem!

» more
 

Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate

» more
 

Eckert & Ziegler is Manufacturing Partner for Bayer’s Innovative Targeted Thorium Conjugates in Europe

» more
 

ProBioGen and Nouscom Sign License Agreement for ProBioGen’s Technology Platform

» more
 

sphingotec is adding an advanced POC testing platform to portfolio

» more
 

Safer liver resection: Perioperative assessment of liver function with the LiMAx® test shortens hospital stay and reduces complications after liver surgery

» more
 

CO.DON negotiates with Xintela on the establishment of a joint venture

» more
 

Scannexus and MRI.TOOLS announce collaboration

» more
 

TissUse establishes a liver-endocrine tissues multi-organ model for risk assessment with Bayer

» more
 

Startupbootcamp Digital Health Berlin announces the 2018 cohort!

» more
 
 

Science and Technology News

 

Charité awarded three new ERC Starting Grants in the field of immunity and infection

Three early career researchers from Charité – Universitätsmedizin Berlin have succeeded in securing funding from the European Union’s flagship funding program. ERC Starting Grants support only the most outstanding research proposals and are awarded at the end of a highly competitive selection process. This year, Charité’s researchers performed remarkably, securing all three ERC Starting Grants awarded to German researchers in the area of immunity and infection. Each of the successful applicants will receive approximately €1.5 million over a period of five years. The ERC Starting Grants provide a generous funding package to excellent projects and the outstanding early career researchers who lead them.

Read more...

 

BCRT and Fraunhofer IZI receive manufacturing authorization for CardAP cells

Scientists at the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) of the Charité – Universitätsmedizin Berlin and the Fraunhofer-Institute for Cell Therapy and Immunology have received the manufacturing authorization for their CardAP cells. The team around Professor Dr. Michael Sittinger and Professor Dr. Carsten Tschöpe succeeded in isolating a completely new cell type from tissue samples of the heart. This cell type offers a treatment option for chronic heart muscle disease that would improve the quality of life of patients. The manufacturing authorisation now granted ensures the quality of the CardAP cell therapy product for patients.

Read more...

 

Breakthrough in genetic engineering: Emmanuelle Charpentier wins Kavli Prize

Emmanuelle Charpentier, director at the Max Planck Institute for Infection Biology in Berlin, is among the winners of the internationally renowned Kavli prize. She is honoured for her pioneering work in developing the CRISPR-Cas9 system, a breakthrough tool for genetic engineering. The award ceremony will take place in Oslo on September 4, 2018.

Read more...

 

Restore Health – Therapies that cure

» more
 

Using telemedicine to increase life expectancy

» more
 

Charité researchers lay the groundwork for drugs with fewer side effects

» more
 

Marking breast implants with tomato DNA to prevent counterfeiting

» more
 

New radiological procedure for the diagnosis of liver disease

» more
 

Charité and BIH develop digital data processing infrastructure

» more
 

Joining forces for immune research

» more
 

How cancer cells hibernate

» more
 

Big step for the therapy of type 2 diabetes

» more
 

BCRT and Fraunhofer IZI receive manufacturing authorization for CardAP cells

» more
 
 

Technology and Cooperation Offers

 

Method and arrangement for identification and correction of optical aberrations

» more
 

Adapter for inserting a dental implant

» more
 


For more News from the cluster healthcare industries click here.

 

Events

 
load images
 
10. - 12.10.2018

Meet the German Capital Region at BioJapan

» more
 
14. - 16.10.2018

World Health Summit

» more
 
17. - 18.10.2018

HIMSS Impact18: Leading Digital Transformation and Big Data in Medicine

» more
 
18.10.2018

Crunchy, crispy and cult – Food analysis and nutrition trends: challenges for analysis and evaluation

» more
 
18.10.2018

RegMed Forum 2018: Smart Medical Devices

» more
 
01. - 02.11.2018

Potsdam Days on Bioanalysis 2018

» more
 
12. - 15.11.2018

MEDICA 2018

» more
 


For more events in the life science region Berlin-Brandenburg click here.



Imprint

The operator and party responsible for content in compliance with § 5 of the German Teleservices Act (TaMG) and in the meaning of the German Press Act:

Berlin Partner for Business and Technology GmbH
Fasanenstraße 85 | 10623 Berlin, Germany
Telephone: +49 30 46302-500
E-Mail: info (at) healthcapital.de

Commercial Registry Entry
Entered in the commercial registry of the Charlottenburg District Court,
Registration number: HRB 13072 B
VAT ID: DE 136629780

CEO:
Dr. Stefan Franzke

Chairman of the Supervisory Board:
Dr. Jürgen Allerkamp 

© 2018 Berlin Partner für Wirtschaft und Technologie GmbH

Unsubscribe from the newsletter
The newsletter of the Cluster healthcare industries Berlin-Brandenburg is a project of Berlin Partner for Business and Technology. Funded by the federal state of Berlin and the European Regional Development fund through the Investitionsbank Berlin.

load images load images
load images